{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010538","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.644176+00:00","generated_at":"2026-06-17T07:11:42.598294+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MolDX publishes Medicare LCD for esophageal cancer testing; effective May 14, 2023","bullets":["Foundational LCD L39256 provides criteria for future coverage of molecular tests like EsoGuard.","LCD incorporates stakeholder feedback from 2022 draft, aligning with ACG guidelines and non-endoscopic testing.","Lucid plans to submit EsoGuard for Technical Assessment later this year after clinical utility data completion.","Company also highlights recent in-network agreement with MultiPlan to expand commercial payer coverage.","Lucid is a majority-owned subsidiary of PAVmed Inc. (PAVM)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010538","json":"https://secwatch.observer/filing/0001493152-23-010538.json","markdown":"https://secwatch.observer/filing/0001493152-23-010538.md","text":"https://secwatch.observer/filing/0001493152-23-010538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/0001493152-23-010538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:11:42.598294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}